和鉑醫藥-B(02142.HK)與ABBVIE及烏特勒支大學合作共同開發HBM9022
格隆匯 12 月 9日丨和鉑醫藥-B(02142.HK)發佈公告，2020年12月3日，AbbVie Inc.(紐約證券交易所：ABBV)、Harbour Antibodies B.V.(公司的直接全資附屬公司)及Utrecht University Holding B.V.與Universiteit Utrecht(“烏特勒支大學”)訂立授權協議，以推進開發全人源COVID-19中和抗體47D11(“HBM9022 (ABBV-47D11)”)，而HBM9022為烏特勒支大學及鹿特丹伊拉斯姆斯大學醫療中心利用公司的和鉑抗體平台共同發現的抗體。
根據授權協議，AbbVie將進行HBM9022 (ABBV-47D11)的臨牀開發，如開發成功，將會生產並於全球將產品商業化。AbbVie(作為獲授權方)將向Harbour Antibodies及烏特勒支大學(作為授權方)支付一次性許可費、里程碑付款及於成功商業化後按銷售淨額支付分級特許使用權費。
誠如招股章程第301及302頁所披露，集團自2020年6月起已與AbbVie、烏特勒支大學及伊拉斯姆斯醫學中心合作。有關合作旨在開發HBM9022 (ABBV47D11)，藉以預防及治療SARS-CoV-2病毒所引致的全球大流行呼吸系統疾病COVID-19。HBM9022 (ABBV-47D11)為公司的其中一項臨牀前階段資產，與公司的任何核心產品概無關連。
伊拉斯姆斯醫學中心與烏特勒支大學及Harbour Antibodies於2020年11月26日訂立專利轉讓協議，據此，其將HBM9022 (ABBV-47D11)相關專利的權利、所有權及權益指讓予烏特勒支大學，並授予烏特勒支大學及Harbour Antibodies向AbbVie 授出獨家授權的權利。伊拉斯姆斯醫學中心並非授權協議的訂約方。
董事確認，公司已根據公司(清盤及雜項條文)條例、《證券及期貨(在證券市場上市)規則》及上市規則於招股章程披露有關全球發售及集團的所有重大資料。董事認為，上文簡述的更新資料不構成須根據上市規則第11.13條刊發補充招股章程的重大資料。因此，上市時間表將維持不變，並預期將於2020年12月10日(星期四)落實上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
